Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Adapted Therapy for Bulky Stage I/II Hodgkin Lymphoma
NCT01118026Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2010
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 4 more in Classical Hodgkin Lymphoma (cHL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-Free Survival at 36 months. Started Sep 2010; status: completed.
02
Drugs
pegylated liposomal doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT01118026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118026.